Your Weekly Nutrition Update
An educational newsletter for all healthcare providers
New Clinical News
Study shows artificial sweeteners rapidly alter glucose response - and not in a good way!
Consumption of non-caloric artificial sweeteners (NAS), commonly found in diet sodas, had a deleterious impact on postprandial glycemic response in healthy subjects, a new double-blind randomized trial found.  Artificially sweetened beverages (ASBs) are thought to be healthier than sugar sweetened beverages because they contain little or no sugar. However, an increasing number of large-scale epidemiological studies have reported an unfavorable association between the  consumption of ASBs and increased risks for T2D, metabolic syndrome (MetS), obesity, CVD and even neurocognitive disorders . ..

Poster Presentation by Dr. Gail Cresci of Cleveland Clinic 
Symptomatic Relief from Small Intestinal Bacterial Overgrowth (SIBO) by probiotic Lactobacillus salivarius UCC118 strain
Gail Cresci, PhD, RD

Daily consumption of the probiotic strain  Lactobacillus salivarius UCC118 appeared to help relieve severity of gastrointestinal (GI) symptoms  associated with small intestinal bacterial overgrowth (SIBO)according to a pilot quality improvement study

The study participants (n=29) were recruited from patients who presented to the Cleveland Clinic Center for Gut Rehabilitation and Transplantation outpatient clinic (Cleveland, OH)...

NEW Podcast with Drs. Mark Kaye & Veronica Gasko
"Nutrition Bites" on Weight Management 

Managing weight loss can be a challenge for many individuals today. Healthcare practitioners (HCPs) are often asked for the most effective methods available in managing Metabolic Syndrome (MetS), type 2 diabetes (T2D) and obesity. In this podcast, Drs. Mark Kaye and Veronica Gasko discuss valuable methods for making lifestyle changes and dietary adjustments...
Insights from Dr. Charles Serhan 
Use of Specialized Pro-Resolving Mediators
in Inflammatory Bowel Disease (IBD)

In this short video with Dr. Serhan of Harvard Medical School, discusses the opportunities to treat IBD and Crohn's Disease with SPMs for resolution of inflammationIn animal models, there are encouraging result on three resolvins: D1; Mar1; and E1. Each of these is able to reduce pro-inflammatory mediators to preserve GI integrity and maintain gut barrier function. Rigorously testing their efficacy in reducing IBD is the next step for determining clinical application

Follow MHICN on Twitter and like us on Facebook for daily news and research